QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

British Journal of Cancer

Volumn 112, Issue 2, 2015, Pages 296-305

  Ghatalia, P ^a   Je, Y ^b   Kaymakcalan, M D ^c   Sonpavde, G ^a   Choueiri, T K ^c  

^a University of Alabama at Birmingham   (United States)

^b Kyung Hee University   (South Korea)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Approved; Cardiac toxicity; Meta analysis; QTc interval prolongation; Tyrosine kinase inhibitors; Vascular endothelial growth factor receptor

Indexed keywords

AXITINIB; CABOZANTINIB; PAZOPANIB; PLACEBO; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ARTICLE; CARDIOVASCULAR RISK; ELECTROCARDIOGRAPHY MONITORING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE TACHYCARDIA; HUMAN; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUDDEN CARDIAC DEATH; TORSADE DES POINTES; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; HEART CONTRACTION; HEART MUSCLE CONDUCTION SYSTEM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; RISK;

ANTINEOPLASTIC AGENTS; ARRHYTHMIAS, CARDIAC; HEART CONDUCTION SYSTEM; HUMANS; MOLECULAR TARGETED THERAPY; MYOCARDIAL CONTRACTION; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK;

EID: 84922337361     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.564     Document Type: Article

References (52)

1. Ahn JS, Lee KH, Sun JM, Park K, Kang ES, Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, Lee JS, Lee JW, Ahn MJ (2013) A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung Cancer 82(3): 455-460.
2. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM (2003) What clinicians should know about the QT interval. JAMA 289(16): 2120-2127.
3. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, Goss G, Chan A, Meharchand J, Alam Y, Gregg R, Butts C, Langmuir P, Shepherd F. National Cancer Institute of Canada Clinical Trials Group Study BR.20 (2007) Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 25(27): 4278-4284.
4. Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121(1): 121-131.
5. Bazett HC (1920) An analysis of the time relations to electrocardiograms. Heart 7: 353-370.
6. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN (2001) The QT interval. Prog Cardiovasc Dis 43(5 Suppl 1): 1-45.
7. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4): 1088-1101.
8. Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L (2009) Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res 15(22): 7045-7052.
9. Bowlin SJ, Xia F, Wang W, Robinson KD, Stanek EJ (2013) Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc 88(2): 139-148.
10. Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK (2010) Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int 105(9): 1247-1254.
11. Cochran W (1954) The combination of estimates from different experiments. Biometrics 10: 101-129.
12. Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, Miller WH, Tassell V, Huang X, Paolini J, Kern KA, Romieu G (2013) Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 31(23): 2870-2878.
13. deBoer R (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 29(8): 1067-1074.
14. Dennis AT, Wang L, Wan H, Nassal D, Deschenes I, Ficker E (2012) Molecular determinants of pentamidine-induced hERG trafficking inhibition. Mol Pharmacol 81(2): 198-209.
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3): 177-188.
16. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109): 629-634.
17. Feinberg BA, Jolly P, Wang ST, Fortner B, Scott J, Gilmore J, Neary MP, Duh MS (2012) Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol 29(2): 786-794.
18. Fridericia LS (1920) The duration of systole in electrocardiogram in normal humans and in patients with heart disease. Acta Med Scan 53: 469-486.
19. Heath EI, Infante J, Lewis LD, Luu T, Stephenson J, Tan AR, Kasubhai S, LoRusso P, Ma B, Suttle AB, Kleha JF, Ball HA, Dar MM (2013) A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemother Pharmacol 71(3): 565-573.
20. Health Canada (2014a) Summary Basis of Decision (SBD): Caprelsa. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2012-caprelsa-126822-eng.php (accessed 13 April 2014).
21. Health Canada (2014b) Summary Basis of Decision (SBD): Sutent. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2007-sutent-101319-eng.php (accessed 13 April 2014).
22. Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood LA (2014) Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 25(1): 149-154.
23. Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11(7): 619-626.
24. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25(27): 4270-4277.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Bmj 327(7414): 557-560.
26. Hodges M, Salerno D, Erlien D (1983) Bazett's QT correction reviewed: evidence that a linear correction for heart rate is better. J Am Coll Cardiol 1: 694.
27. Houk BE, Sarapa N, Pithavala YK (2008) Effect of axitinib (AG-013736) concentration on QT interval after administration alone and in combination with ketoconazole in healthy volunteers (abstract PII-36). Presented at the 109th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
28. Hsu C, Yang TS, Huo TI, Hsieh RK, Yu CW, Hwang WS, Hsieh TY, Huang WT, Chao Y, Meng R, Cheng AL (2012) Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. J Hepatol 56(5): 1097-1103.
29. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1): 1-12.
30. Kim T, Saunder M, Salazar R, Guren T, Sorbye H, Samuel L, Sanders N, Pover S, Im S (2009) A randomized, double-blind, placebo-controlled phase II study of vandetanib plus FOLFIRI in patients with advanced colorectal cancer (CRC). ASCO Gastrointestinal Cancers Symposium, abstract 188.
31. Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E (2011) Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 12(3): 256-262.
32. Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101(7): 587-592.
33. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ (2012) Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 13(9): 897-905.
34. Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C (2012) Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 30(10): 1114-1121.
35. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10): e1-34.
36. Loriot Y, Houede N, Le Moulec S, Hennequin C, Eymard JC, Beuzebec P, Oudard S, Culine S, Tisseron A, Fizazi K (2011) Bicalutamide in combination with vandetanib or placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression - a randomized, double-blind phase II trial. Eur J Cancer 47: S500 poster 7051.
37. Maison-Blanche P, Vermorken JB, Goksel T, Machiels JP, Agarwala S, Rottey S, Daugaard G, Volovat C, Scheulen M, Sengeløv L, Grecea D, Eniu A, Jäger E, Meiri E, Cascinu S, Strumberg D, Demir G, Clemens M, Pinotti G, Nardi M, Guthrie T, Boelle E, Magherini E (2013) A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. J Cardiovasc Pharmacol 61(6): 495-504.
38. Obers S, Staudacher I, Ficker E, Dennis A, Koschny R, Erdal H, Bloehs R, Kisselbach J, Karle CA, Schweizer PA, Katus HA, Thomas D (2010) Multiple mechanisms of hERG liability: K + current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. Naunyn Schmiedebergs Arch Pharmacol 381(5): 385-400.
39. Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS (2014) Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol 44(1): 5-16.
40. Pithavala YK, Tong W, Mount J, Rahavendran SV, Garrett M, Hee B, Selaru P, Sarapa N, Klamerus KJ (2012) Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs 30(1): 273-281.
41. Rimassa L (2013) Vandetanib Gemcitabine or placebo plus Gemcitabine or Vandetanib monotherapy in advanced biliary tract cancer (VANGOGH). http://clinicaltrials.gov/ct2/show/record/NCT00753675 (accessed October 2014).
42. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D (1992) An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 70: 797-801.
43. Sanguinetti MC, Mitcheson JS (2005) Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26(3): 119-124.
44. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26(32): 5204-5212.
45. Shah RR, Morganroth J, Shah DR (2013) Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 36(5): 295-316.
46. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6): 1061-1068.
47. Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25(22): 3362-3371.
48. Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, Sundaresan PR (2011) A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 67(4): 751-764.
49. Van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829): 1879-1886.
50. Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30(2): 134-141.
51. Yang TS, Oh DY, Guimbaud R, Szanto J, Salek T, Thurzo L, Vieitez JM, Pover GM, Kim TW (2009) Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): a randomized, double-blind, placebo-controlled phase II study. J Clin Oncol 27: 15s 2009 (Suppl; abstract 4084).
52. Zipes MD, Libby Peter, Bonow RO, Braunwalk E (2005) Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 7th edn pp 207-251. Saunders: Philadelphia, PA.